Hospitalization Cost of Congenital Syphilis Diagnosis From Insurance Claims Data in the United States

2013 ◽  
Vol 40 (3) ◽  
pp. 226-229 ◽  
Author(s):  
Kwame Owusu-Edusei ◽  
Camille E. Introcaso ◽  
Harrell W. Chesson
Keyword(s):  
United States ◽  
Claims Data ◽  
Congenital Syphilis ◽  
The United States ◽  
Insurance Claims ◽  
Hospitalization Cost ◽  
Insurance Claims Data

scholarly journals Use of Insurance Claims Data to Determine Prevalence and Confirm a Cluster of Sarcoidosis Cases in Vermont

2009 ◽  
Vol 124 (3) ◽  
pp. 442-446 ◽  
Author(s):  
Lori A. Cragin ◽  
A. Scott Laney ◽  
Cortland J. Lohff ◽  
Brennan Martin ◽  
John A. Pandiani ◽  
...  
Keyword(s):  
United States ◽  
Claims Data ◽  
The United States ◽  
Office Building ◽  
Primary Sources ◽  
Local Estimate ◽  
Insurance Claims ◽  
Department Of Health ◽  
Annual Prevalence ◽  
Insurance Claims Data

Objectives. In 2006, the Vermont Department of Health was asked to respond to a potential cluster of sarcoidosis cases related to a Vermont office building. Sarcoidosis prevalence has not been formally described for the United States. A range of <1–40/100,000 is commonly reported; however, we have not identified primary sources supporting this conclusion. Because of the wide prevalence range and lack of a local estimate, confirming existence of a cluster was difficult. Methods. We ascertained the prevalence of sarcoidosis cases in Vermont by using insurance claims data to determine whether or not a cluster of sarcoidosis cases was related to the office building. We calculated county and state annual prevalence proportions for sarcoidosis for 2004 and 2005 and annual building prevalences for 1992–2006. Results. The pooled sarcoidosis case prevalence for Vermont was 66.1/100,000. The pooled building annual prevalence (1,128/100,000) was statistically different from the county in which the building is located (odds ratio = 15.5, 95% confidence interval 3.0, 50.3). Conclusions. We reported the first statewide sarcoidosis prevalence in the United States. This prevalence exceeded previous limited and unsubstantiated U.S. reports. Even with Vermont's elevated sarcoidosis prevalence, the presence of a cluster in this building was apparent.

scholarly journals Telehealth Delivery of Mental Health Services: An Analysis of Private Insurance Claims Data in the United States

2017 ◽  
Vol 68 (12) ◽  
pp. 1303-1306 ◽  
Author(s):  
Fernando A. Wilson ◽  
Sankeerth Rampa ◽  
Kate E. Trout ◽  
Jim P. Stimpson
Keyword(s):  
Mental Health ◽  
United States ◽  
Mental Health Services ◽  
Health Services ◽  
Claims Data ◽  
Private Insurance ◽  
The United States ◽  
Insurance Claims ◽  
Insurance Claims Data

scholarly journals Analysis of coronary angioplasty practice in the United States with an insurance-claims data base.

Circulation ◽  
1993 ◽  
Vol 87 (5) ◽  
pp. 1489-1497 ◽  
Author(s):  
E J Topol ◽  
S G Ellis ◽  
D M Cosgrove ◽  
E R Bates ◽  
D W Muller ◽  
...  
Keyword(s):  
United States ◽  
Data Base ◽  
Coronary Angioplasty ◽  
Claims Data ◽  
The United States ◽  
Insurance Claims ◽  
Insurance Claims Data

scholarly journals Tuberculosis Test Usage and Medical Expenditures from Outpatient Insurance Claims Data, 2013

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Kwame Owusu-Edusei ◽  
Carla A. Winston ◽  
Suzanne M. Marks ◽  
Adam J. Langer ◽  
Roque Miramontes
Keyword(s):  
United States ◽  
Claims Data ◽  
Private Insurance ◽  
Patient Characteristics ◽  
The United States ◽  
Medical Expenditures ◽  
Regression Analyses ◽  
Insurance Claims ◽  
Insurance Claims Data ◽  
Test Usage

Objective. To evaluate TB test usage and associated direct medical expenditures from 2013 private insurance claims data in the United States (US). Methods. We extracted outpatient claims for TB-specific and nonspecific tests from the 2013 MarketScan® commercial database. We estimated average expenditures (adjusted for claim and patient characteristics) using semilog regression analyses and compared them to the Centers for Medicare and Medicaid Services (CMS) national reimbursement limits. Results. Among the TB-specific tests, 1.4% of the enrollees had at least one claim, of which the tuberculin skin test was most common (86%) and least expensive ($9). The T-SPOT® was the most expensive among the TB-specific tests ($106). Among nonspecific TB tests, the chest radiograph was the most used test (78%), while chest computerized tomography was the most expensive ($251). Adjusted average expenditures for the majority of tests (≈74%) were above CMS limits. We estimated that total United States medical expenditures for the employer-based privately insured population for TB-specific tests were $53.0 million in 2013, of which enrollees paid 17% ($9 million). Conclusions. We found substantial differences in TB test usage and expenditures. Additionally, employer-based private insurers and enrollees paid more than CMS limits for most TB tests.

Sign in / Sign up

Export Citation Format

Share Document